Vivos Therapeutics, Inc., a pioneering company in the field of sleep-disordered breathing, is headquartered in the United States. Founded in 2016, Vivos has rapidly established itself as a leader in the dental and medical industries, focusing on innovative solutions for obstructive sleep apnoea (OSA) and related conditions. The company’s flagship product, the Vivos System, offers a unique, non-invasive approach to treating OSA by addressing the underlying anatomical issues rather than merely alleviating symptoms. This distinctive methodology sets Vivos apart in a competitive market, contributing to its growing reputation and market position. With a commitment to improving patient outcomes, Vivos Therapeutics continues to expand its operational reach, making significant strides in the realm of sleep health.
How does Vivos Therapeutics, Inc.'s carbon action stack up? DitchCarbon scores companies based on their carbon action and commitment to reducing emissions. Read about our methodology to learn more.
Mean score of companies in the Medical Device Manufacturing industry. Comparing a company's score to the industry average can give you a sense of how well the company is doing compared to its peers.
Vivos Therapeutics, Inc.'s score of 23 is lower than 65% of the industry. This can give you a sense of how well the company is doing compared to its peers.
Vivos Therapeutics, Inc., headquartered in the US, currently does not report any carbon emissions data, as indicated by the absence of specific figures for Scope 1, Scope 2, and Scope 3 emissions. Consequently, there are no documented reduction targets or climate commitments available at this time. The company has not inherited any emissions data from a parent or related organization, and there are no climate initiatives or pledges reported. As such, Vivos Therapeutics appears to be in the early stages of establishing its climate strategy and emissions reporting framework.
Climate goals typically focus on 2030 interim targets and 2050 net-zero commitments, aligned with global frameworks like the Paris Agreement and Science Based Targets initiative (SBTi) to ensure alignment with global climate goals.
Vivos Therapeutics, Inc. has not publicly committed to specific 2030 or 2050 climate goals through the major frameworks we track. Companies often set interim 2030 targets and long-term 2050 net-zero goals to demonstrate measurable progress toward decarbonization.


You're welcome to quote or reference data from this page, but please include a visible link back to this URL.
Bulk collection, resale, or redistribution of data from multiple profiles is not permitted.
See our License Agreement for more details.